Fluoroestradiol F 18 Brand Name– CERIANNA
What is Fluoroestradiol F 18
Fluoroestradiol F 18 is a parenteral radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
The uptake of fluoroestradiol F 18 is not specific for breast cancer and may occur in a variety of ER-positive tumors that arise outside of the breast, including from the uterus and ovaries.
Therefore, tissue biopsy is necessary to confirm recurrence of breast cancer and to verify ER status by pathology.
Fluoroestradiol F 18 is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).
Indications
- positron emission tomography (PET) imaging
For use with positron emission tomography (PET) imaging to detect estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer
NOTE: Dosage measured in megabecquerels (MBq) and millicuries (mCi).
Side Effects
- dysgeusia
- injection site reaction
Of 1,207 patients with breast cancer receiving at least 1 dose of fluoroestradiol F 18 in clinical studies, injection site reaction (i.e., pain) and dysgeusia were reported in less than 1%.
Monitoring Parameters
- pregnancy testing
Contraindications
- accidental exposure
- breast-feeding
- pregnancy
- pregnancy testing
- radiation exposure
- reproductive risk
Interactions
- Fulvestrant
- Raloxifene
- Selective Estrogen-Receptor Modifiers
- Tamoxifen
- Toremifene
